What medications are recommended for treating seasonal allergic rhinitis in otherwise healthy adults?

Medications for Seasonal Allergies

For initial treatment of seasonal allergic rhinitis in otherwise healthy adults, start with an intranasal corticosteroid (such as fluticasone, mometasone, or budesonide) as monotherapy—this is the single most effective medication class for controlling symptoms.

First-Line Treatment Approach

Intranasal Corticosteroids as Monotherapy

• Intranasal corticosteroids should be prescribed as the primary treatment for seasonal allergic rhinitis in adults aged 12 years and older 1.
• These medications (fluticasone propionate, mometasone, budesonide, triamcinolone) provide superior symptom control compared to all other single-agent therapies 2.
• Do NOT routinely add an oral antihistamine (like cetirizine, loratadine, or fexofenadine) to the intranasal corticosteroid for initial treatment—this combination provides no additional benefit over the intranasal corticosteroid alone 1.

Alternative Monotherapy Options

• If patients prefer oral medication or cannot tolerate intranasal sprays, second-generation oral antihistamines (cetirizine, fexofenadine, desloratadine, loratadine) are appropriate for mild symptoms 2.
• Intranasal antihistamines (azelastine, olopatadine) are effective alternatives and show comparable efficacy to intranasal corticosteroids for moderate-to-severe disease 3.
• Avoid leukotriene receptor antagonists (montelukast) as first-line therapy—intranasal corticosteroids are significantly more effective 1. Montelukast shows clinically meaningful inferior symptom reduction compared to intranasal corticosteroids, though some patients who cannot tolerate nasal sprays may accept this lesser efficacy 1.

When to Escalate Treatment

Combination Therapy for Moderate-to-Severe Disease

• For patients with moderate-to-severe seasonal allergic rhinitis who have inadequate response to monotherapy, consider adding an intranasal antihistamine to the intranasal corticosteroid 1.
• The combination of fluticasone propionate plus azelastine provides greater symptom reduction than either agent alone, with reductions in total nasal symptom scores of -5.31 to -5.7 for combination therapy versus -3.84 to -5.1 for fluticasone alone 1.
• This represents a greater than 40% relative improvement with combination therapy 1.
• This is a weak recommendation due to added cost, potential for adverse effects (dysgeusia in 2-13% of patients, mild somnolence in 0.4-1.1%), and concerns about study bias 1.

Practical Considerations

Symptom-Based Selection

• For mild intermittent symptoms (less than 4 consecutive days/week or less than 4 consecutive weeks/year): use second-generation oral antihistamines or intranasal antihistamines 2.
• For persistent moderate-to-severe symptoms (more than 4 consecutive days/week and more than 4 consecutive weeks/year): initiate intranasal corticosteroid monotherapy 2.
• For prominent ocular symptoms: intranasal antihistamines may provide faster relief (within 3 days) compared to intranasal corticosteroids 3.

Common Pitfalls to Avoid

• Do not use first-generation antihistamines (diphenhydramine, chlorpheniramine)—they cause sedation and are not recommended 4.
• Do not combine intranasal corticosteroids with oral antihistamines for initial treatment—this adds no benefit 1.
• Do not prescribe montelukast as first-line therapy when intranasal corticosteroids are available and tolerated 1.
• Avoid prolonged use of intranasal decongestants (oxymetazoline, phenylephrine) beyond 3-5 days due to rebound congestion risk 5.

Adverse Effect Profile

• Intranasal corticosteroids: epistaxis rates are similar to or lower than placebo; systemic absorption is minimal 1.
• Intranasal antihistamines: dysgeusia (bitter taste) is the most common adverse effect; somnolence is rare at approved doses 1.
• Second-generation oral antihistamines: minimal sedation with cetirizine, fexofenadine, desloratadine, and loratadine 2, 4.

Recent Guideline Updates

• The 2024-2025 ARIA-EAACI guidelines now recommend intranasal corticosteroid plus intranasal antihistamine combinations over either agent alone for many patients, representing a shift toward earlier use of combination therapy 5.
• However, the 2017 Joint Task Force guidelines (from the American Academy of Allergy, Asthma and Immunology and American College of Allergy, Asthma and Immunology) maintain that monotherapy with intranasal corticosteroids should be the initial approach, with combination therapy reserved for inadequate responders 1.